June 26, 2023

Launches Consumer Phase of U.S. Myopia Control Initiative in Conjunction with ECP Early Intervention Messaging

SAN RAMON, CALIF., June 26, 2023—After receiving enthusiastic reaction last week from the eye care community at Optometry’s Meeting in Washington, D.C., CooperVision has launched the consumer phase of its “Make Children’s Sight Your Fight” myopia control advocacy initiative. Rooted in new research that identifies how U.S. parents are seeking information about myopia progression, the back-to-school campaign uses a three-pronged approach to generate awareness, educate and inform, and drive action with parents and eye care professionals (ECPs).

Through significant strategic investments and content partnerships, CooperVision is educating and actively engaging consumers through a comprehensive digital ecosystem with enhanced content across YouTube, Facebook, Instagram, and MiSight.com. A compelling and urgent message emphasizes the need for parents to schedule a comprehensive eye exam for children prior to their return to school. In addition, a collaboration established with a leading U.S consumer healthcare website will deliver articles, videos, and slideshows on myopia and eye-health related content to site visitors seeking information about the disease. The company is also working with national and local market journalists to develop broadcast, streamed, digital, and print feature stories to bring attention to the issue.

“We’ve been inspired by the enthusiastic response to the March ECP-focused launch of the ‘Make Children’s Sight Your Fight’ campaign and practitioners’ heightened commitment to early treatment for as many kids as possible,” said Melissa Kiewe, Vice President of Marketing, Americas, CooperVision. “During this consumer phase, CooperVision is providing parents and caregivers with the resources they need to understand the disease and help them identify and connect with thousands of MiSight® 1 day-certified doctors across the country.”

MiSight® 1 day is the first and only soft contact lens approved by the FDA*  to both correct vision and slow the progression of myopia in children aged 8-12 at the initiation of treatment.†1 It is the only myopia control intervention on the U.S. market—a critical distinction from other myopia management options.

“With myopia expected to affect nearly 50% of North America’s population by 20302, CooperVision strongly advocates for early intervention to slow the progression of this disease. We’re confident that the new messaging and materials we’re providing to parents, and the investment we’re making to widely share them, will help address this epidemic and safeguard the visual health of our children,” said Kiewe.


Both parents and ECPs are encouraged to visit https://coopervision.com/practitioner/ecp-viewpoints/myopia-management for informational resources.


* U.S. Indications for Use: MiSight® 1 day (omafilcon A) soft (hydrophilic) contact lenses for daily wear are indicated for the correction of myopic ametropia and for slowing the progression of myopia in children with non-diseased eyes, who at the initiation of treatment are 8-12 years of age and have a refraction of -0.75 to -4.00 diopters (spherical equivalent) with ≤ 0.75 diopters of astigmatism. The lens is to be discarded after each removal.

Compared to a single vision 1-day lens over a 3-year period.



About CooperVision
CooperVision, a division of CooperCompanies (NYSE:COO), is one of the world’s leading manufacturers of contact lenses. The company produces a full array of daily disposable, two-week and monthly soft contact lenses that feature advanced materials and optics, and premium rigid gas permeable lenses for orthokeratology and scleral designs. CooperVision has a strong heritage of addressing the toughest vision challenges such as astigmatism, presbyopia, childhood myopia and highly irregular corneas; and offers the most complete portfolio of spherical, toric and multifocal products available. Through a combination of innovative products and focused practitioner support, the company brings a refreshing perspective to the marketplace, creating real advantages for customers and wearers. For more information, visit coopervision.com

About CooperCompanies
CooperCompanies ("Cooper") is a global medical device company publicly traded on the NYSE (NYSE:COO). Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to developing a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical is committed to advancing the health of women, babies and families with its diversified portfolio of products and services focusing on medical devices and fertility & genomics. Headquartered in San Ramon, Calif., Cooper has a workforce of more than 15,000 with products sold in over 130 countries. For more information, please visit www.coopercos.com.

Media Contact
Laura DiCaprio, Senior PR Counselor, McDougall Communications
Laura@mcdougallpr.com or +1-585-434-2153


1 Chamberlain P, et al. A 3-year Randomized Clinical Trial of MiSight® Lenses for Myopia Control. Optom Vis Sci. 2019; 96(8)556-567.

Holden BA, et al. Global Prevalence of Myopia and High Myopia and High Myopia and Temporal Trends from 2000 to 2050. Ophthalmology. 2016; 123(5): 1036-1042.